NDLI: Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Please wait, while we are loading the content...

Year: 2017 Volume: 40

Year: 2016 Volume: 39

Year: 2015 Volume: 38

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2010 Volume: 33 Issue: 12

Year: 2010 Volume: 33 Issue: 11

Year: 2010 Volume: 33 Issue: 10

Year: 2010 Volume: 33 Issue: 9

Year: 2010 Volume: 33 Issue: 8

Year: 2010 Volume: 33 Issue: 7

Year: 2010 Volume: 33 Issue: 6

Year: 2010 Volume: 33 Issue: 5

Year: 2010 Volume: 33 Issue: 4

Year: 2010 Volume: 33 Issue: 3

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.

Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios.

The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis.

'First, do no harm': factors that influence pharmacists making decisions about over-the-counter medication: a qualitative study in Northern Ireland.

Year: 2010 Volume: 33 Issue: 2

Year: 2010 Volume: 33 Issue: 1

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chatzizisis, Yiannis S. Koskinas, Konstantinos C. Misirli, Gesthimani Vaklavas, Christos Hatzitolios, Apostolos Giannoglou, George D.
Description	Country affiliation: Greece Author Affiliation: Chatzizisis YS ( 1st Cardiology Department, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki, Greece.)
Abstract	HMG-CoA reductase inhibitors ('statins') represent the most effective and widely prescribed drugs currently available for the reduction of low-density lipoprotein cholesterol, a critical therapeutic target for primary and secondary prevention of cardiovascular atherosclerotic disease. In the face of the established lipid lowering and the emerging pleiotropic properties of statins, the patient population suitable for long-term statin treatment is expected to further expand. An overall positive safety and tolerability profile of statins has been established, although adverse events have been reported. Skeletal muscle-related events are the most common adverse events of statin treatment. Statin-induced myopathy can (rarely) manifest with severe and potentially fatal cases of rhabdomyolysis, thus rendering the identification of the underlying predisposing factors critical. The purpose of this review is to summarize the factors that increase the risk of statin-related myopathy. Data from published clinical trials, meta-analyses, postmarketing studies, spontaneous report systems and case reports for rare effects were reviewed. Briefly, the epidemiology, clinical spectrum and molecular mechanisms of statin-associated myopathy are discussed. We further analyse in detail the risk factors that precipitate or increase the likelihood of statin-related myopathy. Individual demographic features, genetic factors and co-morbidities that may account for the significant interindividual variability in the myopathic risk are presented. Physicochemical properties of statins have been implicated in the differential risk of currently marketed statins. Pharmacokinetic interactions with concomitant medications that interfere with statin metabolism and alter their systemic bioavailability are reviewed. Of particular clinical interest in cases of resistant dyslipidaemia is the interaction of statins with other classes of lipid-lowering agents; current data on the relative safety of available combinations are summarized. Finally, we provide an update of current guidelines for the prevention and management of statin myopathy. The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins.
File Format	HTM / HTML
ISSN	01145916
Issue Number	3
Volume Number	33
e-ISSN	11791942
Journal	Drug Safety
Language	English
Publisher	Springer
Publisher Date	2010-03-01
Publisher Place	New Zealand (Aotearoa)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Toxicology Anticholesteremic Agents Adverse Effects Cholesterol, Ldl Hydroxymethylglutaryl-coa Reductase Inhibitors Muscular Diseases Prevention & Control Risk Assessment Adverse Drug Reaction Reporting Systems Therapeutic Use Cost-benefit Analysis Drug Interactions Drug-related Side Effects And Adverse Reactions Humans Hypolipidemic Agents Chemically Induced Drug Therapy Epidemiology Risk Factors Risk Management Methods Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Toxicology Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in